Cathelicidin LL-37 promotes wound healing in diabetic mice by regulating TFEB-dependent autophagy.
Xi. Liuqing L; Du. Juan J; Xue. Wen W; Shao. Kan K; Jiang. Xiaohong X; Peng. Wenfang W; Li. Wenyi W; Huang. Shan S
Key Findings
- LL‑37 speeds up wound closure in diabetic mice
- Blocking autophagy with 3‑MA stops LL‑37’s healing effect
- LL‑37 activates TFEB, leading to higher levels of autophagy proteins ATG5, ATG7, and BECN1
- Knocking down TFEB removes LL‑37’s ability to promote keratinocyte migration
Practical Outcomes
- LL‑37 shows promise as a topical agent for diabetic wound healing, but the evidence is limited to mouse studies. Biohackers should wait for human safety and dosage data before trying it, and consider that any self‑experiment would be experimental and unproven.
Summary
In diabetic mice, applying the natural peptide LL‑37 helped skin wounds close faster. It works by turning on a cell‑clean‑up system called TFEB‑dependent autophagy, which moves important proteins into the cell nucleus and boosts other autophagy genes. When the autophagy pathway was blocked, the healing benefit disappeared, showing the effect depends on this process.
Abstract
Diabetic patients often experience impaired wound healing. Human cathelicidin LL-37 possesses various biological functions, such as anti-microbial, anti-inflammatory, and pro-wound healing activities. Autophagy has important effects on skin wound healing. However, little is known about whether LL-37 accelerates diabetic wound healing by regulating autophagy. In the study, we aimed to investigate the role of autophagy in LL-37-induced wound healing and uncover the underlying mechanisms involved. A full-thickness wound closure model was established in diabetic mice to evaluate the effects of LL-37 and an autophagy inhibitor (3-MA) on wound healing. The roles of LL-37 and 3-MA in regulating keratinocyte migration were assessed using transwell migration and wound healing assays. The activation of transcription factor EB (TFEB) was measured using western blotting and immunofluorescence (IF) assays of its nuclear translocation. The results showed that LL-37 treatment improved wound healing in diabetic mice, whereas these effects were reversed by 3-MA. In vitro, 3-MA decreased the effects of LL-37 on promoting HaCat keratinocyte migration in the presence of high glucose (HG). Mechanistically, LL-37 promoted TFEB activation and resulted in subsequent activation of autophagy, as evidenced by increased nuclear translocation of TFEB and increased expression of ATG5, ATG7, and beclin 1 (BECN1), whereas these changes were blocked by TFEB knockdown. As expected, TFEB knockdown damaged the effects of LL-37 on promoting keratinocyte migration. Collectively, these results suggest that LL-37 accelerates wound healing in diabetic mice by activating TFEB-dependent autophagy, providing new insights into the mechanism by which LL-37 promotes diabetic wound healing.
Study Information
pubmed
2024
2024-02-28T00:00:00.000Z
10.1016/j.peptides.2024.171183
13
47